Prevail Therapeutics Appoints Industry Leader Francois Nader, M.D., to its Board of Directors

NEW YORK--(BUSINESS WIRE)-- Prevail Therapeutics, Inc. (Prevail), a biotechnology company developing gene therapies for patients with Parkinson's disease and other neurodegenerative diseases, today announced the appointment of Francois Nader, M.D., to its Board of Directors.

Dr. Nader was President, Chief Executive Officer and Executive Director of NPS Pharma from 2008 until 2015, when the company was acquired by Shire for $5.2 billion. During his tenure as CEO, Dr. Nader transformed NPS Pharma into a leading global biotechnology company focused on delivering innovative therapies to patients with rare diseases. Before NPS, Dr. Nader was a Venture Partner at Care Capital. Previously, he served on the North America Leadership Team of Aventis and its predecessor companies, holding a number of executive positions including Senior Vice President of Integrated Healthcare Markets and North America Medical and Regulatory Affairs. Before Aventis, he led global commercial operations at the Pasteur Vaccines division of Rhone-Poulenc. Dr. Nader was recognized as the Ernst and Young National Life Science Entrepreneur of the Year® in 2013. He currently serves as Chairman of the Board of Directors of Acceleron Pharma (NASDAQ: XLRN) and as Board Director of Alexion Pharmaceuticals (NASDAQ: ALXN) and Clementia Pharmaceuticals (NASDAQ: CMTA).

Dr. Nader is also a recognized leader among industry and philanthropic organizations. He is the Chairman of the Jesra Foundation, a trustee of the New Jersey Chamber of Commerce and sits on the Advisory Board of the Open Future Institute. He is a past Chairman of BioNJ, New Jersey's biotechnology trade organization, and has served on the Board of the Biotechnology Industry Organization (BIO), NPS Pharma (NASDAQ: NPSP), Advanced Accelerator Applications (NASDAQ: AAAP), Baxalta (NYSE: BXLT), Trevena (NASDAQ: TRVN) and Noven (NASDAQ: NOVN). Dr. Nader earned his French Doctorate in Medicine from St. Joseph University in Lebanon and his Physician Executive MBA from the University of Tennessee.

"I am honored to join the Board of Prevail Therapeutics," said Dr. Nader. "The Prevail team has already made great progress in developing potential treatments for Parkinson's disease and other neurodegenerative diseases, and I look forward to partnering with the team to help accelerate important therapeutic advances for patients with these devastating illnesses."

"We are very pleased to welcome Dr. Francois Nader, a leading value builder in the biopharma industry, to Prevail's Board of Directors," said Asa Abeliovich, M.D., Ph.D., Founder and Chief Executive Officer of Prevail. "Francois' leadership and proven track record in building and operating biotech companies will be invaluable as we advance our pipeline of gene therapy programs toward the clinic."


Prevail Therapeutics is a biotechnology company focused on developing novel gene therapies for patients with Parkinson's disease and other neurodegenerative diseases. Prevail was launched in 2017 by The Silverstein Foundation for Parkinson's with GBA, REGENXBIO and OrbiMed, and is headquartered in New York, NY.


Katie Engleman, 919-333-7722


Source: Prevail Therapeutics, Inc.

To read more People News articles, click here.